Inovio announces positive HPV vaccine PhIIb results; NanoBio's genital herpes candidate shows efficacy in animal model;

> Inovio Pharmaceuticals ($INO) reported positive Phase IIb studies of its VGX-3100, announcing that in women with high grade cervical neoplasia, the immunotherapy produced killer T cells that were able to clear lesions and the HPV virus itself. Release

> Ann Arbor, MI-based NanoBio announced that its adjuvanted genital herpes vaccine candidate showed efficacy in guinea pigs. Statement

> IDK Biologika opened its first U.S. vaccine manufacturing plant in Rockville, MD. Announcement

> Abivax named Dr. Jean-Marc Steens its chief medical officer. Release

Suggested Articles

Already developing coronavirus treatments, Takeda struck a licensing deal to manufacture and market Novavax's vaccine candidate in Japan

On the heels of last week's deal for 120 million Pfizer-BioNTech shots, Japan has locked down 120 million more vaccines from AstraZeneca.

The pandemic price could be lowered for larger deals, CEO Stephane Bancel said. Pfizer and BioNTech priced 100M doses at $19.50 each for the U.S.